In a placebo-controlled trial, only exercise showed benefit.
A pilot trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with peripheral artery disease (PAD) reported improved walking distance. Its premise was that exercise in PAD causes ischemia-induced production of progenitor cells, which may favorably affect performance.
To further test the hypothesis, investigators randomized 210 participants (mean age, 67; 39% women) with PAD. The study arms were supervised exercise plus GM-CSF, supervised exercise plus placebo, attention control (weekly health lectures) plus GM-CSF, and attention control plus placebo. Treadmill exercise occurred three times a week with an exercise physiologist. The primary outcome was the change from baseline in 6-minute walk distance at 12 weeks (195…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association